The risk of cervical atypia in oral contraceptive users

References

• International Agency for Research on Cancer (IARC). GLOBOCAN. Estimated Cancer Incidence, Mortality and Prevalence worldwide [Internet]. 2012; [cited 2017 April 12]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
   Google Scholar
• Sellors JW, Sankaranarayanan R, Colposcopy and treatment of cervical intraepithelial neoplasia: a beginner’s manual [Internet]. Lyon, France: IARC; 2017. Available from: http://screening.iarc.fr/colpochap.php?lang=1&chap=2
   Google Scholar
• Buckley CH, Butler BE, Fox H. Cervical intraepithelial neoplasia. J Clin Pathol. 1982;35:1–13.
   PubMed Web of Science ®Google Scholar
• Bergeron C. The 2001 Bethesda system. Salud Pública Méx. 2003;45:(3):340–344.
   Google Scholar
• Wright TC, Jr., Massad LS, Dunton CJ, et al. 2006 Consensus Guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007;11:201–222.
   PubMedGoogle Scholar
• Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19.
   PubMed Web of Science ®Google Scholar
• Zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical account . Virology. 2009;384:260–265.
   PubMed Web of Science ®Google Scholar
• Kjellberg L, Hallmans G, Ahren AM, et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer. 2000; 82:1332–1338.
   PubMed Web of Science ®Google Scholar
• Simen-Kapeu A, La Ruche G, Kataja V, et al. Tobacco smoking and chewing as risk factors for multiple human papillomavirus infections and cervical squamous intraepithelial lesions in two countries (Cote d’Ivore and Finland) with different tobacco exposure. Cancer Causes Control. 2009;20:163–170.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Ault KA, Lyytikainen E, et al. Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect. 2011;87:372–376.
   PubMedGoogle Scholar
• Luostarinen T, Namujju PB, Merikukka M, et al. Order of HPV/Chlamydia infections and cervical high-grade precancer risk: a case-cohort study. Int J Cancer. 2013;133:1756–1759.
   PubMed Web of Science ®Google Scholar
• Muwonge R, Ngo Mbus L, Ngoma T, et al. Socio-demographic and reproductive determinants of cervical neoplasia in seven sub-Sahara African countries. Cancer Causes Control. 2016;27:1437–1446.
   PubMed Web of Science ®Google Scholar
• Castellsague X, Munoz N. Chapter 3: cofactors in human papillomavirus carcinogenesis–role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003;20–28.
   PubMedGoogle Scholar
• Ajah LO, Chigbu CO, Ozumba BC, et al. Is there any association between hormonal contraceptives and cervical neoplasia in a poor Nigerian setting? Onco Targets Ther. 2015;8:1887–1892.
   PubMed Web of Science ®Google Scholar
• Syrjänen K, Shabalova I, Petrovichev N, et al. Oral contraceptives are not an independent risk factor for cervical intraepithelial neoplasia or high-risk human papillomavirus infections. Anticancer Res. 2006;26:4729–4740.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Apter D, Dubin G, et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD Aids. 2006;17:517–521.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch XF, et al. Efficacy of a prophylactic adjuvanted L1 VLP vaccine against infection with HPV16/18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial. Lancet. 2007;369:2161–2170.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Paavonen J, Wheeler C, et al. Overall efficacy of HPV-16/18 vaccine against the most stringent cervical pre-cancer end-points: end-of study report of a double blind, randomized trial. Lancet Oncol. 2012;13:89–99.
   PubMed Web of Science ®Google Scholar
• Eriksson T, Torvinen S, Woodhall SC, et al. Impact of HPV16/18 vaccination on quality of life: a pilot study. Eur J Contracept Reprod Health Care. 2013;18:364–371.
   PubMed Web of Science ®Google Scholar
• Woodhall SC, Eriksson T, Nykanen AM, et al. Impact of HPV vaccination on young women's quality of life - a five year follow-up study. Eur J Contracept Reprod Health Care. 2011;16:3–8.
   PubMed Web of Science ®Google Scholar
• Chih HJ, Lee AH, Colville L, et al. Condom and oral contraceptive use and risk of cervical intraepithelial neoplasia in Australian women. J Gynecol Oncol. 2014;25:183–187.
   PubMed Web of Science ®Google Scholar
• Longatto-Filho A, Hammes LS, Sarian LO, et al. Hormonal contraceptives and the length of their use are not independent risk factors for high-risk HPV infections or high-grade CIN. Gynecol Obstet Invest. 2011;71:93–103.
   PubMed Web of Science ®Google Scholar
• Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003;361:1159–1167.
   PubMed Web of Science ®Google Scholar
• Moreno V, Bosch FX, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002;359:1085–1092.
   PubMed Web of Science ®Google Scholar
• Appleby P, Beral V, Berrington de Gonzalez A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370:1609–1621.
   PubMed Web of Science ®Google Scholar
• Zondervan KT, Carpenter LM, Painter R, et al. Oral contraceptives and cervical cancer–further findings from the Oxford family planning association contraceptive study. Br J Cancer. 1996;73:1291–1297.
   PubMed Web of Science ®Google Scholar
• Binesh F, Akhavan A, Pirdehghan A, et al. Does oral contraceptive pill increase the risk of abnormal Pap smear? Iran J Reprod Med. 2013;11:761–766.
   PubMedGoogle Scholar
• Kazerooni T, Mosalaee A. Does contraceptive method change the Pap smear finding? Contraception. 2002;66:243–246.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Papenfuss M, De Galaz EM, et al. Risk factors for squamous intraepithelial lesions (SIL) of the cervix among women residing at the US-Mexico border. Int J Cancer. 2004;109:112–118.
   PubMed Web of Science ®Google Scholar
• kruger-Kjaer S, van den B, Adriaan JC, et al. Different risk factor patterns for high-grade and low-grade intraepithelial lesions on the cervix among HPV-positive and HPV-negative young women. Int J Cancer. 1998;76:613–619.
   PubMed Web of Science ®Google Scholar
• Watson RA. Human papillomavirus: confronting the epidemic-a Urologist's Perspective. Rev Urol. 2005;7:135–144.
   PubMedGoogle Scholar
• Nygard JF, Sauer T, Skjeldestad FE, et al. CIN 2/3 and cervical cancer after an ASCUS pap smear. A 7-year, prospective study of the Norwegian population-based, coordinated screening program. Acta Cytol. 2003;47:991–1000.
   PubMed Web of Science ®Google Scholar
• Nygard JF, Sauer T, Nygard M, et al. CIN 2/3 and cervical cancer in an organised screening programme after an unsatisfactory or a normal Pap smear: a seven-year prospective study of the Norwegian population-based screening programme. J Med Screen. 2004;11:70–76.
   PubMed Web of Science ®Google Scholar
• Sun LL, Chen W, Fan YY, et al. The presence of advanced lesions and associating risk factors for advanced cervical carcinoma in patients with atypical sguamous cells of undetermined significance. Eur J Gynaecol Oncol. 2015;36:585–589.
   PubMed Web of Science ®Google Scholar